The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
This research study looks to enroll as many people diagnosed with lung cancer at 45 years old or younger in order to: * Better understand causes of lung cancer in individuals 45 years old and younger, which is a rare disease * Better estimate lung cancer risks and potential risk factors for lung cancer in individuals 45 years old and younger * Examine tumor (somatic) or normal (germline) genetic changes that may be shared among young lung cancer patients * Improve opportunities for screening and treatment of lung cancer in individuals 45 years old and younger Study procedures will include: * Collecting information from participants' medical record and two (2) short questionnaires * Collecting blood and/or saliva samples * Collecting tumor tissue samples (optional) It is expected that about 500 people will take part in this research study. Participants will be in this study until it closes or the participant withdraws consent.
Study Type
OBSERVATIONAL
Enrollment
500
* Provide research team access to relevant medical records * Answer two (2) short questionnaires at time of consent * Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample * Consider consenting to other optional parts of the research such as: * Providing additional blood or tissue samples in the future (optional) * Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)
Massachusetts General Hospital
Boston, Massachusetts, United States
RECRUITINGBeth Israel Deaconess Medical Center
Boston, Massachusetts, United States
NOT_YET_RECRUITINGBrigham and Women's Hospital
Boston, Massachusetts, United States
NOT_YET_RECRUITINGRepository of specimens and data
Prospective registry of young lung cancer specimens for exploratory tumor and germline genomics, transcriptomics/proteomics, and future biomarker study.
Time frame: 5 years or study closure
Number of patients with targetable somatic alterations in known oncogenic driver genes
Targetable alterations are defined as any somatic alteration in a driver oncogene for which a Food and Drug Administration-approved therapy exists, for which an off-label therapy exists, or for which a clinical trial exists (including but not limited to EGFR, KRAS, ALK, ROS1, RET, MET, BRAF, and TRK). Results will be summarized using descriptive statistics.
Time frame: 5 years or study closure
Number of patients with predicted oncogenic alterations in unknown driver genes
Unknown driver genes include genes not currently known to be driver oncogenes in lung cancer, and for which no directed treatment exists. Results will be summarized using descriptive statistics.
Time frame: 5 years or study closure
Number of patients with pathogenic or likely pathogenic germline alterations in known cancer predisposition genes
Pathogenic or likely pathogenic variants based on classification by the American College of Medical Genetics and Genomics (ACMG). Results will be summarized using descriptive statistics.
Time frame: 5 years or study closure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
RECRUITING